In this Issue:
Discussing physical activity with patients
Nomogram for predicting BRAF mutational status in mCRC
Dietary factors linked to gastric cancer risk
Drug sequence more important than drug exposure in mCRC
Third-line regorafenib not cost-effective in mCRC
Timing of adjuvant chemotherapy linked to survival
Perioperative FOLFOX improves PFS in colorectal liver metastases
Single organ metastases stage IV NSCLC: favourable prognosis
Tumoural dihydropyrimidine dehydrogenase expression: XELOX biomarker?
Nedaplatin + docetaxel in advanced squamous NSCLC
Please login below to download this issue (PDF)